PL4003293T3 - Rozwój farmaceutyczny - Google Patents

Rozwój farmaceutyczny

Info

Publication number
PL4003293T3
PL4003293T3 PL20751254.2T PL20751254T PL4003293T3 PL 4003293 T3 PL4003293 T3 PL 4003293T3 PL 20751254 T PL20751254 T PL 20751254T PL 4003293 T3 PL4003293 T3 PL 4003293T3
Authority
PL
Poland
Prior art keywords
pharmaceutical development
pharmaceutical
development
Prior art date
Application number
PL20751254.2T
Other languages
English (en)
Inventor
Professor Anthony COATES
Yanmin Hu
Original Assignee
Helperby Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helperby Therapeutics Limited filed Critical Helperby Therapeutics Limited
Publication of PL4003293T3 publication Critical patent/PL4003293T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20751254.2T 2019-07-29 2020-07-28 Rozwój farmaceutyczny PL4003293T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1910787.9A GB201910787D0 (en) 2019-07-29 2019-07-29 Pharmaceutical development
PCT/GB2020/051810 WO2021019234A1 (en) 2019-07-29 2020-07-28 Pharmaceutical development

Publications (1)

Publication Number Publication Date
PL4003293T3 true PL4003293T3 (pl) 2025-09-01

Family

ID=67990469

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20751254.2T PL4003293T3 (pl) 2019-07-29 2020-07-28 Rozwój farmaceutyczny

Country Status (9)

Country Link
US (1) US20220257699A1 (pl)
EP (2) EP4003293B1 (pl)
JP (1) JP7743076B2 (pl)
CN (1) CN114514033A (pl)
CA (1) CA3144541A1 (pl)
GB (1) GB201910787D0 (pl)
PL (1) PL4003293T3 (pl)
SA (1) SA522431528B1 (pl)
WO (1) WO2021019234A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112546030A (zh) * 2019-09-26 2021-03-26 盈科瑞(天津)创新医药研究有限公司 一种吸入用多粘菌素e甲磺酸钠溶液及其制备方法
EP3995370B1 (en) * 2020-11-04 2025-04-30 Volvo Truck Corporation A vehicle motion management system and a motion support system for a vehicle
CN113121646B (zh) * 2021-03-02 2022-09-13 河北圣雪大成制药有限责任公司 一种结晶工艺制备多粘菌素甲磺酸钠的方法
CN116203173A (zh) * 2022-12-31 2023-06-02 中国人民解放军空军军医大学 一种基于lc-ms/ms法同时测定人血清中多粘菌素e1和多粘菌素e2浓度的方法
CN119523952A (zh) * 2024-10-17 2025-02-28 河北医科大学 一种多黏菌素吸入液体制剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101879145B (zh) * 2009-09-16 2011-04-20 朗天药业(湖北)有限公司 抗hiv药物注射用齐多夫定及其制备工艺
CN104043103B (zh) * 2013-03-12 2015-08-05 江苏奥赛康药业股份有限公司 一种多黏菌素e甲磺酸钠冻干制剂及其制备方法
GB201305277D0 (en) * 2013-03-22 2013-05-01 Helperby Therapeutics Ltd Novel combination and use
TW201522364A (zh) 2013-06-07 2015-06-16 Xellia Pharmaceuticals Aps 黏菌素甲磺酸鈉(cms)之定性方法
GB201401617D0 (en) * 2014-01-30 2014-03-19 Helperby Therapeutics Ltd Novel combination and use
GB201521771D0 (en) 2015-12-10 2016-01-27 Helperby Therapeutics Ltd Formulation
GB201704620D0 (en) * 2017-03-23 2017-05-10 Helperby Therapeautics Ltd Combinations

Also Published As

Publication number Publication date
JP7743076B2 (ja) 2025-09-24
SA522431528B1 (ar) 2024-07-15
US20220257699A1 (en) 2022-08-18
CN114514033A (zh) 2022-05-17
EP4003293A1 (en) 2022-06-01
CA3144541A1 (en) 2021-02-04
WO2021019234A1 (en) 2021-02-04
EP4003293B1 (en) 2025-06-04
EP4591874A2 (en) 2025-07-30
EP4591874A3 (en) 2025-09-10
JP2022542395A (ja) 2022-10-03
EP4003293C0 (en) 2025-06-04
GB201910787D0 (en) 2019-09-11

Similar Documents

Publication Publication Date Title
IL276232A (en) pharmaceutical compounds
GB201911928D0 (en) Pharmaceutical compounds
GB2572126B (en) Pharmaceutical
GB2569961B (en) Pharmaceutical
GB2572125B (en) Pharmaceutical
GB201810245D0 (en) Pharmaceutical compounds
EP3638658C0 (en) PHARMACEUTICAL COMPOUNDS
GB201911944D0 (en) Pharmaceutical compounds
GB201810239D0 (en) Pharmaceutical compounds
GB201819961D0 (en) Pharmaceutical compounds
PL4003293T3 (pl) Rozwój farmaceutyczny
GB201819960D0 (en) Pharmaceutical compounds
GB201915273D0 (en) Pharmaceutical compounds
GB201915932D0 (en) Pharmaceutical compounds
GB201914910D0 (en) Pharmaceutical compounds
GB201801562D0 (en) Pharmaceutical compounds
GB201901989D0 (en) Pharmaceutical combinations
IL277334A (en) Pharmaceutical combinations
IL291570A (en) Pharmaceutical preparations
GB201800378D0 (en) Pharmaceutical compounds
IL279334A (en) Pharmaceutical combinations
GB201816369D0 (en) Pharmaceutical compounds
IL283273A (en) Pharmacy practices
PL3996688T3 (pl) Preparat farmaceutyczny
ZA202006346B (en) Pharmaceutical preparation